In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Novartis acquires Lek

Executive Summary

Novartis has announced its intention to acquire, through a public tender offer, Slovenian generic pharmaceutical company Lek, offering €426 ($417) per share for all of Lek's 1.9mm outstanding shares--an estimated total purchase price of €826mm ($806mm), or about 2.5 times its 2001 sales.
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register